Pregabalin induced visual hallucinations – a rare adverse reaction

Springer Science and Business Media LLC - 2020
Georgios Mousailidis1, Basavaraja Papanna1, Andrew G. Salmon1, Sein Aung1, Qutaiba Al-Hillawi1
1Essex Partnership Trust, Wickford, UK

Tóm tắt

Abstract Background Pregabalin is an anticonvulsive, analgesic and anxiolytic medication. The typical side effects include dizziness, somnolence and weight gain. Few studies or case reports have demonstrated psychiatric side effects resulting from its use. Case presentation We present a patient who suffered visual hallucinations and agitation associated with an increase in pregabalin dose, resolving completely after pregabalin discontinuation. Conclusions Acute visual hallucinations should be considered in the clinical spectrum of very rare side effects of pregabalin use, especially at higher doses. Tapered discontinuation of the medication can improve and resolve symptoms.

Từ khóa


Tài liệu tham khảo

Bockbrader H, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–9.

Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin – results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947–53.

McKeage K, Keam S. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26:883–92.

Yargic I, Ozdemiroglu F. Pregabalin abuse: a case report. Klinik Psikofarmakoloji Bülteni-Bull Clin Psychopharmacol. 2011;21:64–6.

Filipetto F, Zipp C, Coren J. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110(10):605–7.

Pohl R, Feltner D, Fieve R, Pande A. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151–8.

Baron R, Freynhagen R, Tolle T, Cloutier C, Leon T, Murphy T, Philips K, A0081007 investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150:420–7.

Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–36.

Olaizola I, Ellger T, Young P, Bösebeck F, Evers S, Kelinghaus C. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure. 2006;15:208–10.

Pedroso J, Nakama G, Carneiro-Filho M, Barsottini O. Delirium, psychosis, and visual hallucinations induced by pregabalin. Arq Neuropsiquiatr. 2012;70:960–1.

Chen Z, Lusicic A, O’Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016;139(10):2668–78.

Jablonowski K, Margolese H, Chouinard G. Gabapentin induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatr. 2002;47:975–6.

Kellinghaus C, Dziewas R, Ludemann P. Tiagabine-related nonconvulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure. 2002;11:243–9.

Hickey C, Thomas B. Delirium secondary to pregabalin. Gen Hosp Psychiatry. 2012;34(4):436.e1–2.

Solaro C, Tanganelli P. Acute delirium in patients with multiple sclerosis treated with pregabalin. Clin Neuropharmacol. 2009;32:236–7.

Mezaki N, Tomohiko I, Tetsutaro O, Ryoko T, Osamu O, Takayoshi S. Patient with insidious hypoactive delirium associated with pregabalin. Neurol Clin Neurosci. 2013;1(5):177–8.

Mishriky B, Waldron N, Habib A. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and metaanalysis. Br J Anaesth. 2015;114:10–31.

Taylor C, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–50.

Gundogmus I, Karagoz A, Algul A. Firstepisode psychosis induced by pregabalin withdrawal: a case report. Psychiatry Clin Psychopharmacol. 2018;28(4):461–3.

Bossard J, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality analysis for the assessment of abuse and dependence potential of pregabalin in the French pharmacovigilance database. Clin Drug Investig. 2016;36(9):735–42.

Nordgaard J, Jurgens G. A case of pregabalin abuse. Clin Toxicol. 2013;51(4):320.

Ashton H. Benzodiazepine withdrawal: an unfinished story. Br Med J (Clin Res ed). 1984;288:1135.

Hadley S, Mandel F, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26:461–70.

Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947–57.

Sawant N, Bokdawala R. Pregabalin in the treatment of Charles bonnet syndrome. J Pak Med Assoc. 2013;63(4):530–1.

Tripp A, Golden S. Transient complex visual hallucinations with venlafaxine treatment: a case report. Prim Care Companion J Clin Psychiatry. 2009;11(2):83.

Jacob M, Ash P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy. J Clin Psychiatry. 2009;70(4):601–3.

Bialer M, Johannessen S, Kupferberg H, Levy R, Perrucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the seventh EILAT conference (EILAT VII). Epilepsy Res. 2004;61:1–48.

Javitt D. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010;47(1):4–16.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả